BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35793409)

  • 21. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
    Pierson SK; Shenoy S; Oromendia AB; Gorzewski AM; Langan Pai RA; Nabel CS; Ruth JR; Parente SAT; Arenas DJ; Guilfoyle M; Reddy M; Weinblatt M; Shadick N; Bower M; Pria AD; Masaki Y; Katz L; Mezey J; Beineke P; Lee D; Tendler C; Kambayashi T; Fosså A; van Rhee F; Fajgenbaum DC
    Blood Adv; 2021 Sep; 5(17):3445-3456. PubMed ID: 34438448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.
    Dong Y; Zhang L; Nong L; Wang L; Liang Z; Zhou D; Fajgenbaum DC; Ren H; Li J
    Ann Hematol; 2018 Sep; 97(9):1641-1647. PubMed ID: 29732477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
    Fajgenbaum DC; Wu D; Goodman A; Wong R; Chadburn A; Nasta S; Srkalovic G; Mukherjee S; Leitch H; Jayanthan R; Ferrero S; Sato Y; Schey S; Dispenzieri A; Oksenhendler E; Zinzani PL; Lechowicz MJ; Hoffmann C; Pemmaraju N; Bagg A; Fossa A; Lim MS; van Rhee F;
    Am J Hematol; 2020 Dec; 95(12):1553-1561. PubMed ID: 32894785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.
    Yu L; Tu M; Cortes J; Xu-Monette ZY; Miranda RN; Zhang J; Orlowski RZ; Neelapu S; Boddu PC; Akosile MA; Uldrick TS; Yarchoan R; Medeiros LJ; Li Y; Fajgenbaum DC; Young KH
    Blood; 2017 Mar; 129(12):1658-1668. PubMed ID: 28100459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
    van Rhee F; Voorhees P; Dispenzieri A; Fosså A; Srkalovic G; Ide M; Munshi N; Schey S; Streetly M; Pierson SK; Partridge HL; Mukherjee S; Shilling D; Stone K; Greenway A; Ruth J; Lechowicz MJ; Chandrakasan S; Jayanthan R; Jaffe ES; Leitch H; Pemmaraju N; Chadburn A; Lim MS; Elenitoba-Johnson KS; Krymskaya V; Goodman A; Hoffmann C; Zinzani PL; Ferrero S; Terriou L; Sato Y; Simpson D; Wong R; Rossi JF; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Oksenhendler E; Fajgenbaum DC
    Blood; 2018 Nov; 132(20):2115-2124. PubMed ID: 30181172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances.
    Lang E; van Rhee F
    Blood Rev; 2024 Mar; 64():101161. PubMed ID: 38087716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
    Casper C; Chaturvedi S; Munshi N; Wong R; Qi M; Schaffer M; Bandekar R; Hall B; van de Velde H; Vermeulen J; Reddy M; van Rhee F
    Clin Cancer Res; 2015 Oct; 21(19):4294-304. PubMed ID: 26124203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series.
    Lust H; Gong S; Remiker A; Rossoff J
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29261. PubMed ID: 34302703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review.
    Rehman MEU; Chattaraj A; Neupane K; Rafae A; Saeed S; Basit J; Ibrahim A; Khouri J; Mukherjee S; Anwer F
    Eur J Haematol; 2022 Oct; 109(4):309-320. PubMed ID: 35770616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
    van Rhee F; Rothman M; Ho KF; Fleming S; Wong RS; Fosså A; Dispenzieri A; Cavet J; Munshi N; Vermeulen J; Casper C
    Patient; 2015 Apr; 8(2):207-16. PubMed ID: 25736164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
    Ferrero S; Ragaini S
    J Med Case Rep; 2021 Mar; 15(1):105. PubMed ID: 33676575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical development of siltuximab.
    Davis CC; Shah KS; Lechowicz MJ
    Curr Oncol Rep; 2015 Jul; 17(7):29. PubMed ID: 25986720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
    Tonialini L; Bonfichi M; Ferrero S; Malipiero G; Nozza A; Argnani L; Zinzani PL
    Hematol Oncol; 2018 Oct; 36(4):689-692. PubMed ID: 30074630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.
    Plano F; Mancuso S; Camarda GM; Butera MG; Sucato G; Alecci G; Florena AM; Perrone S; Siragusa SM
    Chemotherapy; 2024; 69(1):35-39. PubMed ID: 37634492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.
    Deisseroth A; Ko CW; Nie L; Zirkelbach JF; Zhao L; Bullock J; Mehrotra N; Del Valle P; Saber H; Sheth C; Gehrke B; Justice R; Farrell A; Pazdur R
    Clin Cancer Res; 2015 Mar; 21(5):950-4. PubMed ID: 25601959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
    Rubenstein AI; Pierson SK; Shyamsundar S; Bustamante MS; Gonzalez MV; Milller ID; Brandstadter JD; Mumau MD; Fajgenbaum DC
    Br J Haematol; 2024 Mar; 204(3):921-930. PubMed ID: 38168727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial.
    Koga T; Hagimori N; Takemori S; Morimoto S; Sumiyoshi R; Shimizu T; Hosogaya N; Fukushima C; Yamamoto H; Kawakami A
    Medicine (Baltimore); 2020 Jul; 99(30):e20710. PubMed ID: 32791665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. van Rhee F, Rosenthal A, Kanhai K, et al. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv. 2022;6(16):4773-4781.
    Blood Adv; 2023 Apr; 7(8):1604-1605. PubMed ID: 37097712
    [No Abstract]   [Full Text] [Related]  

  • 39. Indolent T-Lymphoblastic Proliferation in Idiopathic Multicentric Castleman Disease.
    Karki NR; Arfa AS; Savage N; Kutlar A
    Acta Haematol; 2022; 145(2):214-220. PubMed ID: 34818661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Idiopathic Castleman Disease.
    van Rhee F; Greenway A; Stone K
    Hematol Oncol Clin North Am; 2018 Feb; 32(1):89-106. PubMed ID: 29157622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.